Agents of Last Resort: Polymyxin Resistance

Infectious Disease Clinics of North America

Volumn 30, Issue 2, 2016, Pages 391-414

  Kaye, Keith S ^a   Pogue, Jason M ^a   Tran, Thien B ^b   Nation, Roger L ^b   Li, Jian ^b  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MONASH UNIVERSITY   (Australia)

Author keywords

Colistin; Gram negative; Polymyxin B; Polymyxins; Resistance

Indexed keywords

CARBAPENEM; COLISTIN; DIAMINOBUTYRIC ACID; GALACTOSAMINE; LIPOPOLYSACCHARIDE; PHOSPHOETHANOLAMINE; POLYMYXIN B; POLYMYXIN;

ACINETOBACTER BAUMANNII; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BACTERIAL GENE; BACTERIAL STRAIN; BACTERIUM ISOLATE; ESCHERICHIA COLI; GENE DELETION; HUMAN; HYDROPHOBICITY; KLEBSIELLA PNEUMONIAE; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM SMEGMATIS; NEPHROTOXICITY; NONHUMAN; PHOQ GENE; PMRA GENE; PMRB GENE; PSEUDOMONAS AERUGINOSA; REVIEW; RISK FACTOR; UPREGULATION; DRUG EFFECTS; GRAM NEGATIVE BACTERIUM; GRAM-NEGATIVE BACTERIAL INFECTIONS; MICROBIOLOGY; MULTIDRUG RESISTANCE; PATHOGENICITY; PUBLIC HEALTH;

DRUG RESISTANCE, MULTIPLE, BACTERIAL; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; POLYMYXINS; PUBLIC HEALTH;

EID: 84991383747     PISSN: 08915520     EISSN: 15579824     Source Type: Journal    
DOI: 10.1016/j.idc.2016.02.005     Document Type: Review

References (135)

1. 1 Ortwine, J.K., Kaye, K.S., Li, J., et al. Colistin: understanding and applying recent pharmacokinetic advances. Pharmacotherapy 35:1 (2015), 11–16.
2. 2 Centers for Disease Control and Prevention. Antibiotic resistant threats in the United States, 2013. 2013. Available at: http://www.cdc.gov/drugresistance/pdf/ar-threats-2013-508.pdf. Accessed March 16, 2016.
3. 3 Morrill, H.J., Pogue, J.M., Kaye, K.S., et al. Treatment options for carbapenem-resistant Enterobacteriaceae infections. Open Forum Infect Dis, 2(2), 2015, ofv050.
4. 4 Velkov, T., Thompson, P.E., Nation, R.L., et al. Structure–activity relationships of polymyxin antibiotics. J Med Chem 53:5 (2010), 1898–1916.
5. 5 Bergen, P.J., Li, J., Rayner, C.R., et al. Colistin methanesulfonate is an inactive prodrug of colistin against Pseudomonas aeruginosa. Antimicrob Agents Chemother 50:6 (2006), 1953–1958.
6. 6 He, H., Li, J.C., Nation, R.L., et al. Pharmacokinetics of four different brands of colistimethate and formed colistin in rats. J Antimicrob Chemother 68:10 (2013), 2311–2317.
7. 7 Hancock, R.E., Peptide antibiotics. Lancet 349:9049 (1997), 418–422.
8. 8 Hancock, R.E., Chapple, D.S., Peptide antibiotics. Antimicrob Agents Chemother 43:6 (1999), 1317–1323.
9. 9 Velkov, T., Roberts, K.D., Nation, R.L., et al. Pharmacology of polymyxins: new insights into an 'old' class of antibiotics. Future Microbiol 8:6 (2013), 711–724.
10. 10 Cajal, Y., Rogers, J., Berg, O.G., et al. Intermembrane molecular contacts by polymyxin B mediate exchange of phospholipids. Biochemistry 35:1 (1996), 299–308.
11. 11 Dixon, R.A., Chopra, I., Polymyxin B and polymyxin B nonapeptide alter cytoplasmic membrane permeability in Escherichia coli. J Antimicrob Chemother 18:5 (1986), 557–563.
12. 12 Vincent, J.L., Laterre, P.F., Cohen, J., et al. A pilot-controlled study of a polymyxin B-immobilized hemoperfusion cartridge in patients with severe sepsis secondary to intra-abdominal infection. Shock 23:5 (2005), 400–405.
13. 13 Nishibori, M., Takahashi, H.K., Katayama, H., et al. Specific removal of monocytes from peripheral blood of septic patients by polymyxin B-immobilized filter column. Acta Med Okayama 63:1 (2009), 65–69.
14. 14 Deris, Z.Z., Akter, J., Sivanesan, S., et al. A secondary mode of action of polymyxins against Gram-negative bacteria involves the inhibition of NADH-quinone oxidoreductase activity. J Antibiot 67:2 (2014), 147–151.
15. 15 Mogi, T., Murase, Y., Mori, M., et al. Polymyxin B identified as an inhibitor of alternative NADH dehydrogenase and malate: quinone oxidoreductase from the Gram-positive bacterium Mycobacterium smegmatis. J Biochem 146:4 (2009), 491–499.
16. 16 Basu, S., Radziejewska-Lebrecht, J., Mayer, H., Lipopolysaccharide of Providencia rettgeri. Chemical studies and taxonomical implications. Arch Microbiol 144:3 (1986), 213–218.
17. 17 Boll, M., Radziejewska-Lebrecht, J., Warth, C., et al. 4-Amino-4-deoxy-L-arabinose in LPS of enterobacterial R-mutants and its possible role for their polymyxin reactivity. FEMS Immunol Med Microbiol 8:4 (1994), 329–341.
18. 18 Vinogradov, E., Lindner, B., Seltmann, G., et al. Lipopolysaccharides from Serratia marcescens possess one or two 4-amino-4-deoxy-L-arabinopyranose 1-phosphate residues in the lipid A and D-glycero-D-talo-oct-2-ulopyranosonic acid in the inner core region. Chemistry 12:25 (2006), 6692–6700.
19. 19 Kline, T., Trent, M.S., Stead, C.M., et al. Synthesis of and evaluation of lipid A modification by 4-substituted 4-deoxy arabinose analogs as potential inhibitors of bacterial polymyxin resistance. Bioorg Med Chem Lett 18:4 (2008), 1507–1510.
20. 20 Miller, A.K., Brannon, M.K., Stevens, L., et al. PhoQ mutations promote lipid A modification and polymyxin resistance of Pseudomonas aeruginosa found in colistin-treated cystic fibrosis patients. Antimicrob Agents Chemother 55:12 (2011), 5761–5769.
21. 21 Breazeale, S.D., Ribeiro, A.A., McClerren, A.L., et al. A formyltransferase required for polymyxin resistance in Escherichia coli and the modification of lipid A with 4-Amino-4-deoxy-L-arabinose. Identification and function of UDP-4-deoxy-4-formamido-L-arabinose. J Biol Chem 280:14 (2005), 14154–14167.
22. 22 McPhee, J.B., Lewenza, S., Hancock, R.E., Cationic antimicrobial peptides activate a two-component regulatory system, PmrA-PmrB, that regulates resistance to polymyxin B and cationic antimicrobial peptides in Pseudomonas aeruginosa. Mol Microbiol 50:1 (2003), 205–217.
23. 23 Gunn, J.S., Lim, K.B., Krueger, J., et al. PmrA-PmrB-regulated genes necessary for 4-aminoarabinose lipid A modification and polymyxin resistance. Mol Microbiol 27:6 (1998), 1171–1182.
24. 24 McPhee, J.B., Bains, M., Winsor, G., et al. Contribution of the PhoP-PhoQ and PmrA-PmrB two-component regulatory systems to Mg2+-induced gene regulation in Pseudomonas aeruginosa. J Bacteriol 188:11 (2006), 3995–4006.
25. 25 Olaitan, A.O., Morand, S., Rolain, J.M., Mechanisms of polymyxin resistance: acquired and intrinsic resistance in bacteria. Front Microbiol, 5, 2014, 643.
26. 26 Nowicki, E.M., O'Brien, J.P., Brodbelt, J.S., et al. Extracellular zinc induces phosphoethanolamine addition to Pseudomonas aeruginosa lipid A via the ColRS two-component system. Mol Microbiol 97:1 (2015), 166–178.
27. 27 Adams, M.D., Nickel, G.C., Bajaksouzian, S., et al. Resistance to colistin in Acinetobacter baumannii associated with mutations in the PmrAB two-component system. Antimicrob Agents Chemother 53:9 (2009), 3628–3634.
28. 28 Pelletier, M.R., Casella, L.G., Jones, J.W., et al. Unique structural modifications are present in the lipopolysaccharide from colistin-resistant strains of Acinetobacter baumannii. Antimicrob Agents Chemother 57:10 (2013), 4831–4840.
29. 29 Moffatt, J.H., Harper, M., Harrison, P., et al. Colistin resistance in Acinetobacter baumannii is mediated by complete loss of lipopolysaccharide production. Antimicrob Agents Chemother 54:12 (2010), 4971–4977.
30. 30 Henry, R., Vithanage, N., Harrison, P., et al. Colistin-resistant, lipopolysaccharide-deficient Acinetobacter baumannii responds to lipopolysaccharide loss through increased expression of genes involved in the synthesis and transport of lipoproteins, phospholipids, and poly-beta-1,6-N-acetylglucosamine. Antimicrob Agents Chemother 56:1 (2012), 59–69.
31. 31 Cannatelli, A., Di Pilato, V., Giani, T., et al. In vivo evolution to colistin resistance by PmrB sensor kinase mutation in KPC-producing Klebsiella pneumoniae is associated with low-dosage colistin treatment. Antimicrob Agents Chemother 58:8 (2014), 4399–4403.
32. 32 Jayol, A., Poirel, L., Brink, A., et al. Resistance to colistin associated with a single amino acid change in protein PmrB among Klebsiella pneumoniae isolates of worldwide origin. Antimicrob Agents Chemother 58:8 (2014), 4762–4766.
33. 33 Olaitan, A.O., Diene, S.M., Kempf, M., et al. Worldwide emergence of colistin resistance in Klebsiella pneumoniae from healthy humans and patients in Lao PDR, Thailand, Israel, Nigeria and France owing to inactivation of the PhoP/PhoQ regulator mgrB: an epidemiological and molecular study. Int J Antimicrob Agents 44:6 (2014), 500–507.
34. 34 Cannatelli, A., Giani, T., D'Andrea, M.M., et al. MgrB inactivation is a common mechanism of colistin resistance in KPC-producing Klebsiella pneumoniae of clinical origin. Antimicrob Agents Chemother 58:10 (2014), 5696–5703.
35. 35 Campos, M.A., Vargas, M.A., Regueiro, V., et al. Capsule polysaccharide mediates bacterial resistance to antimicrobial peptides. Infect Immun 72:12 (2004), 7107–7114.
36. 36 Llobet, E., Tomas, J.M., Bengoechea, J.A., Capsule polysaccharide is a bacterial decoy for antimicrobial peptides. Microbiology 154:Pt 12 (2008), 3877–3886.
37. 37 Padilla, E., Llobet, E., Domenech-Sanchez, A., et al. Klebsiella pneumoniae AcrAB efflux pump contributes to antimicrobial resistance and virulence. Antimicrob Agents Chemother 54:1 (2010), 177–183.
38. 38 Li, J., Rayner, C.R., Nation, R.L., et al. Heteroresistance to colistin in multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 50:9 (2006), 2946–2950.
39. 39 Hermes, D.M., Pormann Pitt, C., Lutz, L., et al. Evaluation of heteroresistance to polymyxin B among carbapenem-susceptible and -resistant Pseudomonas aeruginosa. J Med Microbiol 62:Pt 8 (2013), 1184–1189.
40. 40 Poudyal, A., Howden, B.P., Bell, J.M., et al. In vitro pharmacodynamics of colistin against multidrug-resistant Klebsiella pneumoniae. J Antimicrob Chemother 62:6 (2008), 1311–1318.
41. 41 Barin, J., Martins, A.F., Heineck, B.L., et al. Hetero- and adaptive resistance to polymyxin B in OXA-23-producing carbapenem-resistant Acinetobacter baumannii isolates. Ann Clin Microbiol Antimicrob, 12, 2013, 15.
42. 42 Li, J., Nation, R.L., Owen, R.J., et al. Antibiograms of multidrug-resistant clinical Acinetobacter baumannii: promising therapeutic options for treatment of infection with colistin-resistant strains. Clin Infect Dis 45:5 (2007), 594–598.
43. 43 Vidaillac, C., Benichou, L., Duval, R.E., In vitro synergy of colistin combinations against colistin-resistant Acinetobacter baumannii, Pseudomonas aeruginosa, and Klebsiella pneumoniae isolates. Antimicrob Agents Chemother 56:9 (2012), 4856–4861.
44. 44 Beceiro, A., Moreno, A., Fernandez, N., et al. Biological cost of different mechanisms of colistin resistance and their impact on virulence in Acinetobacter baumannii. Antimicrob Agents Chemother 58:1 (2014), 518–526.
45. 45 Hraiech, S., Roch, A., Lepidi, H., et al. Impaired virulence and fitness of a colistin-resistant clinical isolate of Acinetobacter baumannii in a rat model of pneumonia. Antimicrob Agents Chemother 57:10 (2013), 5120–5121.
46. 46 Wand, M.E., Bock, L.J., Bonney, L.C., et al. Retention of virulence following adaptation to colistin in Acinetobacter baumannii reflects the mechanism of resistance. J Antimicrob Chemother 70:8 (2015), 2209–2216.
47. 47 Lopez-Rojas, R., Dominguez-Herrera, J., McConnell, M.J., et al. Impaired virulence and in vivo fitness of colistin-resistant Acinetobacter baumannii. J Infect Dis 203:4 (2011), 545–548.
48. 48 Humphries, R.M., Susceptibility testing of the polymyxins: where are we now?. Pharmacotherapy 35:1 (2015), 22–27.
49. 49 Nation, R.L., Li, J., Cars, O., et al. Framework for optimisation of the clinical use of colistin and polymyxin B: the Prato polymyxin consensus. Lancet Infect Dis 15:2 (2015), 225–234.
50. 50 Morrow, B.J., Pillar, C.M., Deane, J., et al. Activities of carbapenem and comparator agents against contemporary US Pseudomonas aeruginosa isolates from the CAPITAL surveillance program. Diagn Microbiol Infect Dis 75:4 (2013), 412–416.
51. 51 Tunyapanit, W., Pruekprasert, P., Laoprasopwattana, K., et al. In vitro activity of colistin against multidrug-resistant Pseudomonas aeruginosa isolates from patients in Songklanagarind Hospital, Thailand. Southeast Asian J Trop Med Public Health 44:2 (2013), 273–280.
52. 52 Mohanty, S., Maurya, V., Gaind, R., et al. Phenotypic characterization and colistin susceptibilities of carbapenem-resistant of Pseudomonas aeruginosa and Acinetobacter spp. J Infect Dev Ctries 7:11 (2013), 880–887.
53. 53 Schulin, T., In vitro activity of the aerosolized agents colistin and tobramycin and five intravenous agents against Pseudomonas aeruginosa isolated from cystic fibrosis patients in southwestern Germany. J Antimicrob Chemother 49:2 (2002), 403–406.
54. 54 Yau, W., Owen, R.J., Poudyal, A., et al. Colistin hetero-resistance in multidrug-resistant Acinetobacter baumannii clinical isolates from the Western Pacific region in the SENTRY antimicrobial surveillance programme. J Infect 58:2 (2009), 138–144.
55. 55 Gales, A.C., Jones, R.N., Sader, H.S., Global assessment of the antimicrobial activity of polymyxin B against 54 731 clinical isolates of Gram-negative bacilli: report from the SENTRY antimicrobial surveillance programme (2001-2004). Clin Microbiol Infect 12:4 (2006), 315–321.
56. 56 Gales, A.C., Reis, A.O., Jones, R.N., Contemporary assessment of antimicrobial susceptibility testing methods for polymyxin B and colistin: review of available interpretative criteria and quality control guidelines. J Clin Microbiol 39:1 (2001), 183–190.
57. 57 Cai, Y., Chai, D., Wang, R., et al. Colistin resistance of Acinetobacter baumannii: clinical reports, mechanisms and antimicrobial strategies. J Antimicrob Chemother 67:7 (2012), 1607–1615.
58. 58 Dobrewski, R., Savov, E., Bernards, A.T., et al. Genotypic diversity and antibiotic susceptibility of Acinetobacter baumannii isolates in a Bulgarian hospital. Clin Microbiol Infect 12:11 (2006), 1135–1137.
59. 59 Ko, K.S., Suh, J.Y., Kwon, K.T., et al. High rates of resistance to colistin and polymyxin B in subgroups of Acinetobacter baumannii isolates from Korea. J Antimicrob Chemother 60:5 (2007), 1163–1167.
60. 60 Arroyo, L.A., Garcia-Curiel, A., Pachon-Ibanez, M.E., et al. Reliability of the E-test method for detection of colistin resistance in clinical isolates of Acinetobacter baumannii. J Clin Microbiol 43:2 (2005), 903–905.
61. 61 Arroyo, L.A., Mateos, I., Gonzalez, V., et al. In vitro activities of tigecycline, minocycline, and colistin-tigecycline combination against multi- and pandrug-resistant clinical isolates of Acinetobacter baumannii group. Antimicrob Agents Chemother 53:3 (2009), 1295–1296.
62. 62 Baadani, A.M., Thawadi, S.I., El-Khizzi, N.A., et al. Prevalence of colistin and tigecycline resistance in Acinetobacter baumannii clinical isolates from 2 hospitals in Riyadh Region over a 2-year period. Saudi Med J 34:3 (2013), 248–253.
63. 63 Munoz-Price, L.S., Poirel, L., Bonomo, R.A., et al. Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases. Lancet Infect Dis 13:9 (2013), 785–796.
64. 64 Giani, T., Arena, F., Vaggelli, G., et al. Large nosocomial outbreak of colistin-resistant KPC carbapenemase-producing Klebsiella pneumoniae by clonal expansion of an mgrB deletion mutant. J Clin Microbiol 53:10 (2015), 3341–3344.
65. 65 Ah, Y.M., Kim, A.J., Lee, J.Y., Colistin resistance in Klebsiella pneumoniae. Int J Antimicrob Agents 44:1 (2014), 8–15.
66. 66 Neonakis, I.K., Samonis, G., Messaritakis, H., et al. Resistance status and evolution trends of Klebsiella pneumoniae isolates in a university hospital in Greece: ineffectiveness of carbapenems and increasing resistance to colistin. Chemotherapy 56:6 (2010), 448–452.
67. 67 Kontopidou, F., Plachouras, D., Papadomichelakis, E., et al. Colonization and infection by colistin-resistant Gram-negative bacteria in a cohort of critically ill patients. Clin Microbiol Infect 17:11 (2011), E9–E11.
68. 68 Strenger, V., Gschliesser, T., Grisold, A., et al. Orally administered colistin leads to colistin-resistant intestinal flora and fails to prevent faecal colonisation with extended-spectrum beta-lactamase-producing enterobacteria in hospitalised newborns. Int J Antimicrob Agents 37:1 (2011), 67–69.
69. 69 Halaby, T., Al Naiemi, N., Kluytmans, J., et al. Emergence of colistin resistance in Enterobacteriaceae after the introduction of selective digestive tract decontamination in an intensive care unit. Antimicrob Agents Chemother 57:7 (2013), 3224–3229.
70. 70 Meletis, G., Tzampaz, E., Sianou, E., et al. Colistin heteroresistance in carbapenemase-producing Klebsiella pneumoniae. J Antimicrob Chemother 66:4 (2011), 946–947.
71. 71 Samonis, G., Maraki, S., Karageorgopoulos, D.E., et al. Synergy of fosfomycin with carbapenems, colistin, netilmicin, and tigecycline against multidrug-resistant Klebsiella pneumoniae, Escherichia coli, and Pseudomonas aeruginosa clinical isolates. Eur J Clin Microbiol Infect Dis 31:5 (2012), 695–701.
72. 72 Souli, M., Galani, I., Antoniadou, A., et al. An outbreak of infection due to beta-Lactamase Klebsiella pneumoniae Carbapenemase 2-producing K. pneumoniae in a Greek University Hospital: molecular characterization, epidemiology, and outcomes. Clin Infect Dis 50:3 (2010), 364–373.
73. 73 Souli, M., Kontopidou, F.V., Papadomichelakis, E., et al. Clinical experience of serious infections caused by Enterobacteriaceae producing VIM-1 metallo-beta-lactamase in a Greek University Hospital. Clin Infect Dis 46:6 (2008), 847–854.
74. 74 Papadimitriou-Olivgeris, M., Christofidou, M., Fligou, F., et al. The role of colonization pressure in the dissemination of colistin or tigecycline resistant KPC-producing Klebsiella pneumoniae in critically ill patients. Infection 42:5 (2014), 883–890.
75. 75 Monaco, M., Giani, T., Raffone, M., et al. Colistin resistance superimposed to endemic carbapenem-resistant Klebsiella pneumoniae: a rapidly evolving problem in Italy, November 2013 to April 2014. Euro Surveill, 19(42), 2014 [pii:20939].
76. 76 Qureshi, Z.A., Hittle, L.E., O'Hara, J.A., et al. Colistin-resistant Acinetobacter baumannii: beyond carbapenem resistance. Clin Infect Dis 60:9 (2015), 1295–1303.
77. 77 Meletis, G., Oustas, E., Botziori, C., et al. Containment of carbapenem resistance rates of Klebsiella pneumoniae and Acinetobacter baumannii in a Greek hospital with a concomitant increase in colistin, gentamicin and tigecycline resistance. New Microbiol 38:3 (2015), 417–421.
78. 78 Li, J., Nation, R.L., Turnidge, J.D., et al. Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections. Lancet Infect Dis 6:9 (2006), 589–601.
79. 79 Zavascki, A.P., Goldani, L.Z., Li, J., et al. Polymyxin B for the treatment of multidrug-resistant pathogens: a critical review. J Antimicrob Chemother 60:6 (2007), 1206–1215.
80. 80 Nation, R.L., Velkov, T., Li, J., Colistin and polymyxin B: peas in a pod, or chalk and cheese?. Clin Infect Dis 59:1 (2014), 88–94.
81. 81 Cheah, S., Wang, J., Nguyen, V., et al. New pharmacokinetic/pharmacodynamic studies of systemically administered colistin against Pseudomonas aeruginosa and Acinetobacter baumannii in mouse thigh and lung infection models: smaller response lung infection. J Antimicrob Chemother 70:12 (2015), 3291–3297.
82. 82 Bergen, P.J., Bulitta, J.B., Forrest, A., et al. Pharmacokinetic/pharmacodynamic investigation of colistin against Pseudomonas aeruginosa using an in vitro model. Antimicrob Agents Chemother 54:9 (2010), 3783–3789.
83. 83 Sorli, L., Luque, S., Grau, S., et al. Trough colistin plasma level is an independent risk factor for nephrotoxicity: a prospective observational cohort study. BMC Infect Dis, 13, 2013, 380.
84. 84 Forrest A, Silveira FP, Thamlikitkul V, et al. Toxicodynamics for colistin-associated changes in creatinine clearance. Paper Presented at Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC, 2014.
85. 85 Nation, R.L., Li, J., Cars, O., et al. Consistent global approach on reporting of colistin doses to promote safe and effective use. Clin Infect Dis 58:1 (2014), 139–141.
86. 86 Nation, R.L., Li, J., Turnidge, J.D., The urgent need for clear and accurate information on the polymyxins. Clin Infect Dis 57:11 (2013), 1656–1657.
87. 87 Forrest A, Silveira FP, Thamlikitkul V. Risk factors for colistin-associated nephrotoxicity. Paper Presented at 1st International Conference on Polymyxins. Prato (Italy), May 2–4, 2013.
88. 88 Kumar, A., Roberts, D., Wood, K.E., et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 34:6 (2006), 1589–1596.
89. 89 Nation, R.L., Li, J., Optimizing use of colistin and polymyxin B in the critically ill. Semin Respir Crit Care Med 28:6 (2007), 604–614.
90. 90 Li, J., Milne, R.W., Nation, R.L., et al. A simple method for the assay of colistin in human plasma, using pre-column derivatization with 9-fluorenylmethyl chloroformate in solid-phase extraction cartridges and reversed-phase high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl 761:2 (2001), 167–175.
91. 91 Li, J., Milne, R.W., Nation, R.L., et al. Simple method for assaying colistin methanesulfonate in plasma and urine using high-performance liquid chromatography. Antimicrob Agents Chemother 46:10 (2002), 3304–3307.
92. 92 Landersdorfer, C.B., Nation, R.L., Colistin: how should it be dosed for the critically ill?. Semin Respir Crit Care Med 36:1 (2015), 126–135.
93. 93 Plachouras, D., Karvanen, M., Friberg, L.E., et al. Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by Gram-negative bacteria. Antimicrob Agents Chemother 53:8 (2009), 3430–3436.
94. 94 Mohamed, A.F., Karaiskos, I., Plachouras, D., et al. Application of a loading dose of colistin methanesulfonate in critically ill patients: population pharmacokinetics, protein binding, and prediction of bacterial kill. Antimicrob Agents Chemother 56:8 (2012), 4241–4249.
95. 95 Garonzik, S.M., Li, J., Thamlikitkul, V., et al. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob Agents Chemother 55:7 (2011), 3284–3294.
96. 96 Li, J., Rayner, C.R., Nation, R.L., et al. Pharmacokinetics of colistin methanesulfonate and colistin in a critically ill patient receiving continuous venovenous hemodiafiltration. Antimicrob Agents Chemother 49:11 (2005), 4814–4815.
97. 97 Marchand, S., Frat, J.P., Petitpas, F., et al. Removal of colistin during intermittent haemodialysis in two critically ill patients. J Antimicrob Chemother 65:8 (2010), 1836–1837.
98. 98 Zavascki, A.P., Goldani, L.Z., Cao, G., et al. Pharmacokinetics of intravenous polymyxin B in critically ill patients. Clin Infect Dis 47:10 (2008), 1298–1304.
99. 99 Li, J., Milne, R.W., Nation, R.L., et al. Pharmacokinetics of colistin methanesulphonate and colistin in rats following an intravenous dose of colistin methanesulphonate. J Antimicrob Chemother 53:5 (2004), 837–840.
100. 100 Sandri, A.M., Landersdorfer, C.B., Jacob, J., et al. Population pharmacokinetics of intravenous polymyxin B in critically ill patients: implications for selection of dosage regimens. Clin Infect Dis 57:4 (2013), 524–531.
101. 101 Westerman, E.M., Le Brun, P.P., Touw, D.J., et al. Effect of nebulized colistin sulphate and colistin sulphomethate on lung function in patients with cystic fibrosis: a pilot study. J Cyst Fibros 3:1 (2004), 23–28.
102. 102 Bergen, P.J., Li, J., Nation, R.L., et al. Comparison of once-, twice- and thrice-daily dosing of colistin on antibacterial effect and emergence of resistance: studies with Pseudomonas aeruginosa in an in vitro pharmacodynamic model. J Antimicrob Chemother 61:3 (2008), 636–642.
103. 103 Tam, V.H., Schilling, A.N., Vo, G., et al. Pharmacodynamics of polymyxin B against Pseudomonas aeruginosa. Antimicrob Agents Chemother 49:9 (2005), 3624–3630.
104. 104 Markantonis, S.L., Markou, N., Fousteri, M., et al. Penetration of colistin into cerebrospinal fluid. Antimicrob Agents Chemother 53:11 (2009), 4907–4910.
105. 105 Ziaka, M., Markantonis, S.L., Fousteri, M., et al. Combined intravenous and intraventricular administration of colistin methanesulfonate in critically ill patients with central nervous system infection. Antimicrob Agents Chemother 57:4 (2013), 1938–1940.
106. 106 Lee, J.Y., Chung, E.S., Na, I.Y., et al. Development of colistin resistance in pmrA-, phoP-, parR- and cprR-inactivated mutants of Pseudomonas aeruginosa. J Antimicrob Chemother 69:11 (2014), 2966–2971.
107. 107 Imberti, R., Cusato, M., Villani, P., et al. Steady-state pharmacokinetics and BAL concentration of colistin in critically Ill patients after IV colistin methanesulfonate administration. Chest 138:6 (2010), 1333–1339.
108. 108 Yappa, S.W.S., Li, J., Patel, K., et al. Pulmonary and systemic pharmacokinetics of inhaled and intravenous colistin methanesulfonate in cystic fibrosis patients: targeting advantage of inhalational administration. Antimicrob Agents Chemother 58:5 (2014), 2570–2579.
109. 109 Athanassa, Z.E., Markantonis, S.L., Fousteri, M.Z., et al. Pharmacokinetics of inhaled colistimethate sodium (CMS) in mechanically ventilated critically ill patients. Intensive Care Med 38:11 (2012), 1779–1786.
110. 110 Landersdorfer, C.B., Ly, N.S., Xu, H., et al. Quantifying subpopulation synergy for antibiotic combinations via mechanism-based modeling and a sequential dosing design. Antimicrob Agents Chemother 57:5 (2013), 2343–2351.
111. 111 Delcour, A.H., Outer membrane permeability and antibiotic resistance. Biochim Biophys Acta 1794:5 (2009), 808–816.
112. 112 White, R.L., Burgess, D.S., Manduru, M., et al. Comparison of three different in vitro methods of detecting synergy: time-kill, checkerboard, and E test. Antimicrob Agents Chemother 40:8 (1996), 1914–1918.
113. 113 Ni, W., Shao, X., Di, X., et al. In vitro synergy of polymyxins with other antibiotics for Acinetobacter baumannii: a systematic review and meta-analysis. Int J Antimicrob Agents 45:1 (2015), 8–18.
114. 114 Zusman, O., Avni, T., Leibovici, L., et al. Systematic review and meta-analysis of in vitro synergy of polymyxins and carbapenems. Antimicrob Agents Chemother 57:10 (2013), 5104–5111.
115. 115 Pankey, G.A., Ashcraft, D.S., Detection of synergy using the combination of polymyxin B with either meropenem or rifampin against carbapenemase-producing Klebsiella pneumoniae. Diagn Microbiol Infect Dis 70:4 (2011), 561–564.
116. 116 Aoki, N., Tateda, K., Kikuchi, Y., et al. Efficacy of colistin combination therapy in a mouse model of pneumonia caused by multidrug-resistant Pseudomonas aeruginosa. J Antimicrob Chemother 63:3 (2009), 534–542.
117. 117 Ly, N.S., Bulitta, J.B., Rao, G.G., et al. Colistin and doripenem combinations against Pseudomonas aeruginosa: profiling the time course of synergistic killing and prevention of resistance. J Antimicrob Chemother 70:5 (2015), 1434–1442.
118. 118 Lora-Tamayo, J., Murillo, O., Bergen, P.J., et al. Activity of colistin combined with doripenem at clinically relevant concentrations against multidrug-resistant Pseudomonas aeruginosa in an in vitro dynamic biofilm model. J Antimicrob Chemother 69:9 (2014), 2434–2442.
119. 119 Deris, Z.Z., Yu, H.H., Davis, K., et al. The combination of colistin and doripenem is synergistic against Klebsiella pneumoniae at multiple inocula and suppresses colistin resistance in an in vitro pharmacokinetic/pharmacodynamic model. Antimicrob Agents Chemother 56:10 (2012), 5103–5112.
120. 120 Lee, H.J., Bergen, P.J., Bulitta, J.B., et al. Synergistic activity of colistin and rifampin combination against multidrug-resistant Acinetobacter baumannii in an in vitro pharmacokinetic/pharmacodynamic model. Antimicrob Agents Chemother 57:8 (2013), 3738–3745.
121. 121 Yilmaz, G.R., Guven, T., Guner, R., et al. Colistin alone or combined with sulbactam or carbapenem against A. baumannii in ventilator-associated pneumonia. J Infect Dev Ctries 9:5 (2015), 476–485.
122. 122 Paul, M., Carmeli, Y., Durante-Mangoni, E., et al. Combination therapy for carbapenem-resistant Gram-negative bacteria. J Antimicrob Chemother 69:9 (2014), 2305–2309.
123. 123 Durante-Mangoni, E., Signoriello, G., Andini, R., et al. Colistin and rifampicin compared with colistin alone for the treatment of serious infections due to extensively drug-resistant Acinetobacter baumannii: a multicenter, randomized clinical trial. Clin Infect Dis 57:3 (2013), 349–358.
124. 124 Aydemir, H., Akduman, D., Piskin, N., et al. Colistin vs. the combination of colistin and rifampicin for the treatment of carbapenem-resistant Acinetobacter baumannii ventilator-associated pneumonia. Epidemiol Infect 141:6 (2013), 1214–1222.
125. 125 Santimaleeworagun, W., Wongpoowarak, P., Chayakul, P., et al. In vitro activity of colistin or sulbactam in combination with fosfomycin or imipenem against clinical isolates of carbapenem-resistant Acinetobacter baumannii producing OXA-23 carbapenemases. The Southeast Asian journal of tropical medicine and public health 42:4 (Jul 2011), 890–900.
126. 126 Di, X., Wang, R., Liu, B., et al. In vitro activity of fosfomycin in combination with colistin against clinical isolates of carbapenem-resistant Pseudomas aeruginosa. The Journal of antibiotics, Mar 25 2015.
127. 127 Wei, W., Yang, H., Liu, Y., et al. In vitro synergy of colistin combinations against extensively drug-resistant Acinetobacter baumannii producing OXA-23 carbapenemase. J Chemother, May 15 2015 1973947815Y0000000030.
128. 128 Sirijatuphat, R., Thamlikitkul, V., Preliminary study of colistin versus colistin plus fosfomycin for treatment of carbapenem-resistant Acinetobacter baumannii infections. Antimicrobial agents and chemotherapy 58:9 (Sep 2014), 5598–5601.
129. 129 Centers for Disease Prevention. Management of Multidrug-Resistant Organisms In Healthcare Settings, 2006. 2009; http://www.cdc.gov/hicpac/mdro/mdro_glossary.html. Accessed August 26, 2015.
130. 130 Schwaber, M.J., Lev, B., Israeli, A., et al. Containment of a country-wide outbreak of carbapenem-resistant Klebsiella pneumoniae in Israeli hospitals via a nationally implemented intervention. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 52:7 (Apr 1 2011), 848–855.
131. 131 Hayden, M.K., Lin, M.Y., Lolans, K., et al. Prevention of colonization and infection by Klebsiella pneumoniae carbapenemase-producing enterobacteriaceae in long-term acute-care hospitals. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 60:8 (Apr 15 2015), 1153–1161.
132. 132 Schwaber, M.J., Carmeli, Y., An ongoing national intervention to contain the spread of carbapenem-resistant enterobacteriaceae. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 58:5 (Mar 2014), 697–703.
133. 133 Goel, G., Hmar, L., Sarkar De, M., et al. Colistin-resistant Klebsiella pneumoniae: report of a cluster of 24 cases from a new oncology center in eastern India. Infection control and hospital epidemiology 35:8 (2014), 1076–1077.
134. 134 Pogue, J.M., Kaye, K.S., Cohen, D.A., et al. Appropriate antimicrobial therapy in the era of multidrug-resistant human pathogens. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 21:4 (2015), 302–312.
135. 135 Kaye, K.S., Antimicrobial de-escalation strategies in hospitalized patients with pneumonia, intra-abdominal infections, and bacteremia. Journal of hospital medicine 7:Suppl 1 (2012), S13–S21.